Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer”

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team”

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, driven by reduced Berubicin trial costs. R&D expenses rose to $1.2 million from $1.1 million on preparation for a TPI … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://ibn.fm/JKPUq About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series”